Other Information
−Removed: During the first quarter of 2024,
+Added: During the second quarter of
2024, none of our directors or executive officers adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule
8 unchanged sentences
Incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
−Removed: Amendment No.
−Removed: 1 to Financing Agreement, dated March 29, 2024.
−Removed: Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 2, 2024.
Certification of Chief Executive Officer pursuant to 18 U.S.C.
10 unchanged sentences
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
+Added: ** Provided herewith.
Pursuant to the requirements of the Securities
1 unchanged sentence
OptimizeRx Corporation
+Added: August 14, 2024
/s/ William J.
2 unchanged sentences
OptimizeRx Corporation
+Added: August 14, 2024
/s/ Edward Stelmakh
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.